Wheeler Bio has announced the appointment of Patrick Lucy as its new Chief Executive Officer, signalling a key leadership shift as the company moves towards expanding its contract development and manufacturing (CDMO) capabilities. With more than 32 years of experience
Cellipont Bioservices has entered into an agreement with biopharmaceutical company Mongoose Bio to support the technology transfer, process development, and clinical-grade manufacturing of Mongoose’s autologous TCR-T cell therapy, MGB-001. The partnership will focus on delivering this advanced therapy, designed to
Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organization (CDMO), has named Darren Head as its new Chief Executive Officer. Head, who also serves as Chairman of the Board, brings over 26 years of experience in biopharmaceutical leadership and
RTI Surgical announced the acquisition of Collagen Solutions, a global supplier of medical-grade collagen and xenograft tissue used in various therapeutic areas such as cardiac, sports medicine, and orthopaedics. The move strengthens RTI’s soft tissue portfolio, following its earlier acquisition
Curia, a global contract research, development, and manufacturing organisation (CDMO), has announced its commitment to set near- and long-term greenhouse gas (GHG) emission reduction targets. The targets will align with the Science Based Targets initiative (SBTi) and are part of
Kindeva Drug Delivery has announced two major milestones at its Bridgeton, Missouri facility, highlighting the site’s progress in injectable fill-finish capabilities. The company completed its first registration batch on its high-volume vial line, signalling the readiness of the site to
Curia, a contract research, development, and manufacturing organisation (CDMO), has announced a brand refresh that highlights its capabilities in small molecules, generic active pharmaceutical ingredients (APIs), and biologics. This update, which includes new service logos and a revamped website, aims
Simtra BioPharma Solutions, a contract development and manufacturing organisation (CDMO) specialising in sterile injectables, has announced a $14 million investment aimed at expanding its clinical-scale conjugation and purification services for Antibody-Drug Conjugates (ADCs). The investment is part of Simtra’s broader
Dark Horse Consulting Group (DHC) has introduced the Initiative for Certification of Manufacturing Capabilities (ICMC), aiming to address growing concerns in the cell and gene therapy (CGT) CDMO market. The program is designed to offer unbiased evaluations of CDMO manufacturing
GBI Biomanufacturing, a contract development and manufacturing organization (CDMO), has entered a partnership with Allterum Therapeutics to produce Allterum’s lead cancer therapy candidate, 4A10. The monoclonal antibody (mAb), which targets CD127, will be manufactured for Phase 1/2a clinical trials. The
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
